A5073887999- Acute Ischemic Stroke Management
- Neurological Disorders and Treatments
- Stroke Rehabilitation and Recovery
- Antiplatelet Therapy and Cardiovascular Diseases
- Cerebrovascular and Carotid Artery Diseases
- Venous Thromboembolism Diagnosis and Management
- Blood Pressure and Hypertension Studies
- Neurological Disease Mechanisms and Treatments
- S100 Proteins and Annexins
- Biochemical effects in animals
- Intracerebral and Subarachnoid Hemorrhage Research
- Botulinum Toxin and Related Neurological Disorders
- Cardiac Health and Mental Health
- Coronary Interventions and Diagnostics
Samara Regional Clinical Hospital named after V.D. Seredavina
2015-2025
Samara Regional Clinical Oncology Center
2022
Thales (Portugal)
2020-2021
Thrombolytic therapy (TLT) of ischemic stroke (IS) with alteplase within the first 4.5 hours from onset symptoms is most effective and proven method treatment. Objective: to evaluate safety efficacy TLT Revelisa (alteplase) in IS real-world clinical practice. Material methods. The results were analyzed 1181 patients IS: 616 (52.2%) women 565 (47.8%) men (mean age 68.28±12.56 years), which 140 (11.9%) staged reperfusion. mean time disease was 2.58±0.83 hours. Heidelberg classification used...
To investigate the efficacy and safety of non-immunogenic staphylokinase (NS) compared with alteplase (A) in patients acute ischemic stroke (AIS) within 4.5 h after symptom onset.336 IS onset were included a randomized, open-label, multicenter, parallel-group, non-inferiority comparative trial NS vs A (168 each group). was administered as an intravenous bolus dose 10 mg, regardless body weight, over s, infusion 0.9 mg/kg, maximum 90 mg 1 hour. The primary endpoint favorable outcome, defined...
To evaluate an effect of long-term sequential therapy with mexidol and forte on the functional outcome patients carotid ischemic stroke.The study included 50 newly developed stroke, hospitalized in stroke unit first day from onset disease. Patients main group (n=25) received a dose 500 mg intravenously once for 14 days, then 250 tabs 3 times 60 days. comparison standard basic therapy. The significance intergroup differences was assessed using Mann-Whitney test, Fisher's exact relative risk...
Research objective - studying of results a comprehensive neuro-rehabilitation patients in the acute ischemic stroke (according to Samara regional vascular centre).A review work RVC on main indicators for 2014, detailed analysis 20 period stroke, which treatment was used drug mexidol with dynamics standardized assessment scales (NIHSS, Rankin, Rivermead, MoCA, HADS).The use «Mexidol» leads significant statistically and clinically improvement cognitive, motor, sensory functions, reduction...
Evaluation of the safety and effectiveness thrombolytic therapy (TLT) with drug Revelisa (alteplase) in patients ischemic stroke (AI) real clinical practice.An open prospective multicenter non-interventional register study was conducted, which included 550 AI - 259 (47.1%) women 291 (52.9%) men; average age 67.7±12.6 years. All underwent TLT within 4.5 hours from onset disease and, according to protocol reperfusion AI, clinical, instrumental laboratory examinations were performed....
To assess the safety and efficacy of Revelisa in patients with ischemic stroke real-world clinical practice.The interim analysis an open-label, prospective, multicenter, non-interventional study IVT-AIS-R included 223 (50.2% women 49.8% men, mean age 66.6 (13.5) years) who were admitted to sites since July 2019 who, absence contraindications, underwent thrombolytic therapy (TLT) within first 4.5 hours from onset stroke. Data collected as a continuous sample. According reperfusion protocol...
Post-stroke depression significantly impairs functional recovery in patients and their quality of life. Objective : to evaluate the efficacy vortioxetine correcting depressive symptoms early period ischemic stroke, as well its effect on cognitive functions patients. Patients methods. The investigation enrolled 60 with stroke carotid bed mild moderate according Montgomery-Asberg Depression Rating Scale (MADRS). Group 1 (a study group) included 30 who received 10 mg/day for 8 weeks; 2...
The purpose of the work was to study effect neuroprotective therapy with Cellex on features recovery movement disorders in patients acute period ischemic stroke.A single-center randomized conducted assess efficacy and safety use stroke. included 60 a stroke duration no more than 3 days middle cerebral artery area vertebrobasillar moderate severe central hemiparesis. Patients group received 1 ml Cellex. subcutaneously time per day for 10 days. All drug rehabilitation measures within framework...